We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 55.00 | 45.00 | 65.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVRP LONDON, May 04, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Piers Morgan, Chief Financial Officer of Verona Pharma, will present at BioEURquity Europe 2018 to be held May 14-16, 2018 in Ghent, Belgium. Piers Morgan, Chief Financial Officer is scheduled to present Tuesday, May 15(th) at 5:20 PM CEST. For more information please visit www.veronapharma.com About Verona Pharma plc Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has shown clinically meaningful and statistically significant improvements in lung function and clinical symptoms as compared to placebo, and has shown statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma. For further information, please contact: Verona Pharma plc Tel: +44 (0)20 3283 4200 Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600 and UK Broker) Stewart Wallace / Jonathan Senior / Ben Maddison SNELVeronaPharma@stifel.com FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000 Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com ICR, Inc. (US Media and Investor enquiries) James Heins Tel: +1 203-682-8251 James.Heins@icrinc.com Stephanie Carrington Tel. +1 646-277-1282 Stephanie.Carrington@icrinc.com This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Verona Pharma plc via Globenewswire http://www.veronapharma.com/
(END) Dow Jones Newswires
May 04, 2018 08:30 ET (12:30 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Verona Pharma Chart |
1 Month Verona Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions